WHO to skip Phase 2 and start Phase 3 Ebola vaccine trials in 2-4 weeks

http://globalnews.ca/news/1764343/first-large-ebola-vaccine-trial-2-4-weeks-off/

The plan in Liberia is to test the two most advanced experimental vaccines in a three-armed trial involving 2,700 people. One third will receive a vaccine being made by GSK (formerly GlaxoSmithKline), one third will receive a vaccine being made by NewLink Genetics and Merck and the remaining portion will receive a placebo.

The NewLink-Merck vaccine was designed by researchers at Canada’s National Microbiology Laboratory in Winnipeg.

The idea behind the trial is to give the vaccine to healthy people, and then watch to see how many in each arm develops Ebola. If many people in the placebo group become infected and none or few in the vaccine groups do, it would become clear that the vaccines were protective.

Full article

Advertisements

One thought on “WHO to skip Phase 2 and start Phase 3 Ebola vaccine trials in 2-4 weeks

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s